OMEROS CORP (OMER)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$6.6M
Cash & Equivalents
$14.5M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$744M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
NARSOPLIMAB-WUUG
YARTEMLEA |
APPROVED | Anterior Cruciate Ligament Reconstruction, Atypical Hemolytic Uremic Syndrome, C3 Glomerulopathy, C3G, Cataract, Cataract Extraction, Congenital Cataract, Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA), Hematopoietic Stem Cell Transplantation, Heroin Dependence, Huntington's Disease, Idiopathic Immune Complex-Mediated Glomerulonephritis, IgA Nephropathy, IgAN, Intraocular Lens Replacement, Intraoperative Floppy Iris Syndrome, Kidney Stones, Knee Injuries, Meniscal Tear, Nicotine Dependence, Opioid Abuse, Pain Reduction, Paroxysmal Nocturnal Hemoglobinuria, Postoperative Pain, Renal Calculi, Schizophrenia, Thrombotic Microangiopathies, Unilateral Cataract Extraction, Urinary Calculi, Urinary Stones, Urinary Tract Stones |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06209736 | Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN | PHASE2 | Recruiting | 20 |
| NCT06298955 | Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria | PHASE2 | Recruiting | 25 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.